<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303196</url>
  </required_header>
  <id_info>
    <org_study_id>17-014144</org_study_id>
    <nct_id>NCT03303196</nct_id>
  </id_info>
  <brief_title>Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes</brief_title>
  <official_title>Bihormonal Bionic Pancreas for the Treatment of Diabetes Post-Pancreatectomy in Children With Congenital Hyperinsulinism - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study designed to determine if the bihormonal bionic pancreas provides
      improved blood glucose control, compared to the current standard of care, in individuals with
      hyperinsulinism who developed diabetes after having a pancreatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The management of diabetes following pancreatectomy for hyperinsulinism (HI) generally
      consists of the same approaches that are used for individuals with type 1 diabetes (T1D).
      However, there are significant differences in individuals with HI and post-pancreatectomy
      diabetes that increases the risk of hypoglycemia in these individuals and prevent achieving
      tight glycemic control. Individuals with HI have glucagon deficiency and unlike T1D, those
      with HI and post-pancreatectomy diabetes have residual dysregulated insulin secretion that
      results in marked hypo- and hyper-glycemia. Furthermore, pancreatic insufficiency can result
      in disturbances in nutrient absorption and fluctuations in glucose concentrations.

      Current treatment approaches with intermittent subcutaneous insulin administration or insulin
      pump therapy offer inadequate glycemic control in these individuals. We propose a novel
      approach to the management of these individuals with the bihormonal bionic pancreas to
      replace both hormones, insulin and glucagon, through an automated glycemic management system.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be an open-label, pilot clinical trial to assess efficacy and safety of the bihormonal bionic pancreas in children and young adults with HI who have developed post-pancreatectomy diabetes. Subjects will be studied during two research inpatient admissions at the CHOP HI Center. The order of the interventions will be randomized.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean plasma glucose level.</measure>
    <time_frame>Days 2-3 of each admission</time_frame>
    <description>Mean plasma glucose concentration, as measured by the Continuous glucose monitoring system (CGMS), during the final 3 days of the Bihormonal Bionic Pancreas Admission compared to the Standard Care Admission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean proportion of hypoglycemia.</measure>
    <time_frame>Days 2-3 of each admission</time_frame>
    <description>Mean proportion of time that the CGMS-measured plasma glucose concentration was less than 60 mg/dL during Bihormonal Bionic Pancreas Admission compared to the Standard Care Admission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean CGMS-defined plasma glucose level.</measure>
    <time_frame>Days 2-3 of each admission</time_frame>
    <description>Average plasma glucose level as measured by the CGMS during Bihormonal Bionic Pancreas Admission compared to the Standard Care Admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in pre-defined glucose ranges.</measure>
    <time_frame>Days 2-3 of each admission</time_frame>
    <description>Fraction of time spent within each of the following glucose ranges:
&lt; 50 mg/dL
&lt; 60 mg/dL
&lt; 70 mg/dL
70-120 mg/dL
70-180 mg/dL
&gt;180 mg/dL and
&gt;250 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of non-hyperglycemic subjects.</measure>
    <time_frame>Days 2-3 of each admission</time_frame>
    <description>Percentage of subjects with mean CGMS &lt; 154 mg/dL (estimated average glucose corresponding to an A1c of 7%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of hypoglycemic episodes among subjects.</measure>
    <time_frame>Days 2-3 of each admission</time_frame>
    <description>Percentage of schedule fingerstick checks &lt; 70 mg/dL, &lt; 60 mg/dL, &lt;50 mg/dL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Hyperinsulinism</condition>
  <condition>Diabetes</condition>
  <condition>Pancreatic Diseases</condition>
  <condition>Pancreatectomy; Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Bihormonal Bionic Pancreas Admission</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four day inpatient admission where participants will have blood sugar managed by the Bihormonal Bionic Pancreas. Blood sugars will be monitored for safety by study staff.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care Admission</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Four day inpatient admission where participants will have blood sugar managed by the participant's home-glucose control regimen. Blood sugars will be monitored for safety by study staff.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bihormonal Bionic Pancreas</intervention_name>
    <description>A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.</description>
    <arm_group_label>Bihormonal Bionic Pancreas Admission</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females age 6 to 30 years.

          2. Diagnosis of hyperinsulinism.

          3. Previous pancreatectomy.

          4. Diabetes confirmed by one or more of the following:

               -  Glycosylated A1c &gt; 6.4%.

               -  Fasting glucose &gt; 125 mg/dL.

               -  2-hour post-prandial glucose &gt; 200 mg/dL.

               -  Random glucose &gt; 200 mg/dL with symptomatic hyperglycemia.

          5. On insulin therapy with a regimen of at least 11 units/kg/day.

          6. Treatment with subcutaneous insulin by pump at the time of recruitment.

          7. Prescription medication regimen stable for &gt; 1 month (except for medications that will
             not affect the safety of the study and are not expected to affect any outcome of the
             study, in the judgment of the site PI).

          8. Females &gt; 11 years of age must have a negative urine/serum pregnancy test and must use
             an acceptable method of contraception, including abstinence, a barrier method
             (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the
             study.

          9. Informed consent, parental/guardian permission (informed consent) and if appropriate,
             child assent.

        Exclusion Criteria:

          1. Unable to provide informed consent (e.g. impaired cognition or judgment).

          2. Evidence of a medical condition that might alter results or compromise the
             interpretation of results, including active infection, kidney failure, severe liver
             dysfunction, severe respiratory or cardiac failure.

          3. Evidence of severe hematologic abnormality including severe anemia and/or
             thrombocytopenia.

          4. Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be
             susceptible to radio frequency interference.

          5. Unable to completely avoid acetaminophen for duration of study.

          6. History of adverse reaction to glucagon (including allergy) besides nausea and
             vomiting.

          7. Established history of allergy or severe reaction to adhesive or tape that must be
             used in the study.

          8. Use oral (e.g. thiazolidinediones, biguanides, sulfonylureas, glitinides, dipeptidyl
             peptidase-4 (DPP-4) inhibitors, Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors
             anti-diabetic medications.

          9. Any investigational drug use within 30 days prior to enrollment.

         10. Pregnant or lactating females.

         11. Parents/guardians or subjects who, in the opinion of the Investigator, may be
             non-compliant with study schedules or procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diva D De Leon, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arpana Rayannavar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren M Mitteer, MEd, CCRP</last_name>
    <phone>(267) 426-9915</phone>
    <email>MitteerL@email.chop.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren M Mitteer, MEd, CCRP</last_name>
      <email>MitteerL@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Diva D De Leon, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arpana Rayannavar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.chop.edu/centers-programs/congenital-hyperinsulinism-center</url>
    <description>Children's Hospital of Philadelphia | Congenital Hyperinsulinism Center Website</description>
  </link>
  <link>
    <url>http://www.artificialpancreas.org/</url>
    <description>Boston University | Bionic Pancreas Website</description>
  </link>
  <reference>
    <citation>Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care. 2012 Nov;35(11):2148-55. doi: 10.2337/dc12-0071. Epub 2012 Aug 24.</citation>
    <PMID>22923666</PMID>
  </reference>
  <reference>
    <citation>El-Khatib FH, Russell SJ, Magyar KL, Sinha M, McKeon K, Nathan DM, Damiano ER. Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. J Clin Endocrinol Metab. 2014 May;99(5):1701-11. doi: 10.1210/jc.2013-4151. Epub 2014 Jan 31.</citation>
    <PMID>24483160</PMID>
  </reference>
  <reference>
    <citation>Russell SJ, Hillard MA, Balliro C, Magyar KL, Selagamsetty R, Sinha M, Grennan K, Mondesir D, Ekhlaspour L, Zheng H, Damiano ER, El-Khatib FH. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol. 2016 Mar;4(3):233-243. doi: 10.1016/S2213-8587(15)00489-1. Epub 2016 Feb 3. Erratum in: Lancet Diabetes Endocrinol. 2018 Mar;6(3):e3.</citation>
    <PMID>26850709</PMID>
  </reference>
  <reference>
    <citation>El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, Mondesir D, Esmaeili A, Hartigan C, Thompson MJ, Malkani S, Lock JP, Harlan DM, Clinton P, Frank E, Wilson DM, DeSalvo D, Norlander L, Ly T, Buckingham BA, Diner J, Dezube M, Young LA, Goley A, Kirkman MS, Buse JB, Zheng H, Selagamsetty RR, Damiano ER, Russell SJ. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017 Jan 28;389(10067):369-380. doi: 10.1016/S0140-6736(16)32567-3. Epub 2016 Dec 20. Erratum in: Lancet. 2017 Feb 4;389(10068):e2. Erratum in: Lancet. 2017 Jan 28;389(10067):368.</citation>
    <PMID>28007348</PMID>
  </reference>
  <reference>
    <citation>De Le√≥n DD, Stanley CA. Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab. 2007 Jan;3(1):57-68. Review.</citation>
    <PMID>17179930</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2017</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Diva De Leon</investigator_full_name>
    <investigator_title>Director, Congenital Hyperinsulinism Center</investigator_title>
  </responsible_party>
  <keyword>Post-Pancreatectomy Diabetes</keyword>
  <keyword>Insulin Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

